U.S. Next Generation Cancer Diagnostics Market Size & Outlook
Related Markets
U.S. next generation cancer diagnostics market highlights
- The U.S. next generation cancer diagnostics market generated a revenue of USD 5,127.0 million in 2024 and is expected to reach USD 10,994.1 million by 2033.
- The U.S. market is expected to grow at a CAGR of 8.8% from 2025 to 2033.
- In terms of segment, next generation sequencing was the largest revenue generating technology in 2024.
- Next Generation Sequencing is the most lucrative technology segment registering the fastest growth during the forecast period.
Next generation cancer diagnostics market data book summary
| Market revenue in 2024 | USD 5,127.0 million |
| Market revenue in 2033 | USD 10,994.1 million |
| Growth rate | 8.8% (CAGR from 2025 to 2033) |
| Largest segment | Next generation sequencing |
| Fastest growing segment | Next Generation Sequencing |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Next Generation Sequencing, QPCR & Multiplexing, LOAC & RT-PCR, Protein Microarrays, DNA Microarrays |
| Key market players worldwide | Johnson & Johnson, Illumina Inc, Novartis AG ADR, Roche, Koninklijke Philips NV, Qiagen NV, Agilent Technologies Inc, Abbott Laboratories, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc Common Stock |
Other key industry trends
- In terms of revenue, U.S. accounted for 30.9% of the global next generation cancer diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. next generation cancer diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 1,227.4 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Next Generation Cancer Diagnostics Market Scope
Next Generation Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Agilent Technologies Inc | View profile | 17700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | https://www.agilent.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Koninklijke Philips NV | View profile | 73712 | Philips Center, Amstelplein 2, Amsterdam, Netherlands, 1096 BC | https://www.philips.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| GE HealthCare Technologies Inc Common Stock | View profile | 51000 | 500 West Monroe Street, Chicago, IL, United States, 60661 | https://www.gehealthcare.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
U.S. next generation cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to next generation cancer diagnostics market will help companies and investors design strategic landscapes.
Next generation sequencing was the largest segment with a revenue share of 37.36% in 2024. Horizon Databook has segmented the U.S. next generation cancer diagnostics market based on next generation sequencing, qpcr & multiplexing, loac & rt-pcr, protein microarrays, dna microarrays covering the revenue growth of each sub-segment from 2021 to 2033.
According to the data published by the American Cancer Society, it has been estimated that there were nearly 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in 2014 in the U.S.
Furthermore, population diagnosed with colorectal cancer was estimated to be 71,830 men and 65,000 women and mortality rate of 26,270 men and 24,040 women was estimated by National Center for Health Statistics.
Additionally, one third of the population (29% of men and 43% of women) were affected, mostly individuals above 80 years and older with substantial variation in tumor location by age.
Reasons to subscribe to U.S. next generation cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. next generation cancer diagnostics market databook
-
Our clientele includes a mix of next generation cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. next generation cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. next generation cancer diagnostics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
US Cancer Type - Next Generation Cancer Diagnostics Market size, 2024 - 2033 (US$M)
U.S. Next Generation Cancer Diagnostics Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
